Progression of retinal pigment epithelial atrophy in stargardt disease

American Journal of Ophthalmology

Volumn 154, Issue 1, 2012, Pages 146-154

  McBain, Vikki A ^a   Townend, John ^b   Lois, Noemi ^a  

^a NHS GRAMPIAN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE IMAGING; CLINICAL ARTICLE; DISEASE COURSE; DISEASE DURATION; ELECTROPHYSIOLOGY; ELECTRORETINOGRAM; FEMALE; FOLLOW UP; HUMAN; MALE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; RETINA CONE; RETINA DISEASE; RETINA MACULOPATHY; RETINA ROD; RETINAL PIGMENT EPITHELIAL ATROPHY; STARGARDT DISEASE; VISUAL ACUITY;

ADULT; AGED; ATROPHY; CORNEAL DYSTROPHIES, HEREDITARY; DISEASE PROGRESSION; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MALE; MIDDLE AGED; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDIES; VISUAL ACUITY; YOUNG ADULT;

EID: 84862761654     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.01.019     Document Type: Article

References (33)

1. Stargardt K. Uber familiare progressive degeneration in der makulagegend des auges. Albrecht von Graefes Arch Klin Ophthalmol 1909;71:534-550.
2. Franceschetti A, Francois J. Fundus flavimaculatus. Arch Ophthalmol 1965(6);25:505-530.
3. Blacharski PA. Fundus flavimaculatus. In: Newsome DA, ed. Retinal Dystrophies and Degenerations. 1st ed. New York: Raven Press Ltd; 1988:135-159.
4. Allikmets R. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 1997;15(3):236-246. (Pubitemid 27098715)
5. Kaplan J, Gerber S, Larget-Piet D, et al. A gene for Stargardt's disease (fundus flavimaculatus) maps to the short arm of chromosome 1. Nat Genet 1993;5(3):308-311.
6. Armstrong JD, Meyer D, Xu S, Elfervig JL. Long-term follow-up of Stargardt's disease and fundus flavimaculatus. Ophthalmology 1998;105(3):448-458. (Pubitemid 28125098)
7. Hadden OB, Gass JDM. Fundus flavimaculatus and Stargardt's disease. Am J Ophthalmol 1976;82(4):527-539.
8. Klien BA, Krill AE. Fundus flavimaculatus. Clinical, functional, and histopathologic observations. Am J Ophthalmol 1967;64(1):3-23.
9. Rotenstreich Y, Fishman GA, Anderson RJ. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology 2003;110(6):1151-1158. (Pubitemid 36676647)
10. Aaberg TM. Stargardt's disease and fundus flavimaculatus: Evaluation of morphologic progression and intrafamilial co-existence. Trans Am Ophthalmol Soc 1986;84:453-487. (Pubitemid 17110248)
11. Lois N, Holder GE, Bunce C, Fitzke FW, Bird AC. Phenotypic subtypes of Stargardt macular dystrophy-fundus flavimaculatus. Arch Ophthalmol 2001;119(3):359-369. (Pubitemid 32207258)
12. Fishman GA. Fundus flavimaculatus. Arch Ophthalmol 1976;94(12):2061-2067.
13. Oh KT, Weleber RG, Oh DM, Billingslea AM, Rosenow J, Stone EM. Clinical phenotype as a prognostic factor in Stargardt disease. Retina 2004;24(2):254-262. (Pubitemid 38509613)
14. Lois N, Holder GE, Fitzke FW, Plant C, Bird AC. Intrafamilial variation of phenotype in Stargardt macular dystrophy- Fundus flavimaculatus. Invest Ophthalmol Vis Sci 1999;40(11):2668-2675. (Pubitemid 29455498)
15. Lois N, Halfyard AS, Bird AC, Holder GE, Fitzke FW. Fundus autofluorescence in Stargardt macular dystrophyfundus flavimaculatus. Am J Ophthalmol 2004;138(1):55-63. (Pubitemid 38850249)
16. McBain VA, Lois N. Fundus autofluorescence in Stargardt disease. In: Lois N, Forrester JV, eds. Fundus Autofluorescence. 1st ed. Philadelphia, PA: Lippincott; 2009:206-216.
17. Chen B, Tosha C, Gorin MB, Nusinowitz S. Analysis of autofluorescent retinal images and measurement of atrophic lesion growth in Stargardt disease. Exp Eye Res 2010;91(2):143-152.
18. Smith RT, Gomes NL, Barile G, Busuioc M, Lee N, Laine A. Lipofuscin & autofluorescence metrics in progressive Stargardt disease. Invest Ophthalmol Vis Sci 2009;50(8):3907-3914.
19. Arden GB, Carter RM, Hogg CR, Siegel IM, Margolis S. A gold foil electrode: extending the horizons for clinical electroretinography. Invest Ophthalmol Vis Sci 1979;18(4):421-426. (Pubitemid 9125568)
20. Holder GE, Brigell MG, Hawlina M, Meigen Vaegan T, Bach M. ISCEV standard for clinical pattern electroretinogram -2007 update. Doc Ophthalmol 2007;114(3):111-116. (Pubitemid 46681692)
21. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV standard for clinical electroretinography (2008 update). Doc Ophthalmol 2009;118(1):69-77.
22. Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HP, Schmitz-Valckenberg S, FAM-Study Group. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007;143(3):463-472.
23. Lois N, Owens SL, Coco R, Hopkins J, Fitzke FW, Bird AC. Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss. Am J Ophthalmol 2002;133(3):341-349. (Pubitemid 34171584)
24. Sunness JS, Applegate CA, Haselwood D, Rubin GS. Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease. Ophthalmology 1996;103(9):1458-1466. (Pubitemid 26353053)
25. Radu RA, Mata NL, Bagla A, Travis GH. Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt's macular degeneration. Proc Natl Acad Sci U S A 2004;101(16):5928-5933. (Pubitemid 38520505)
26. Maiti P, Kong J, Kim SR, Sparrow JR, Allikmets R, Rando RR. Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formation. Biochemistry 2006;45(29):852-860. (Pubitemid 43122249)
27. Radu RA, Mata NL, Nusinowitz S, Liu X, Sieving PA, Travis GH. Treatment with Isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci U S A 2003;100(8):4742- 4747. (Pubitemid 36457800)
28. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005;46(12):4393-4401. (Pubitemid 44264531)
29. Radu RA, Yuan Q, Hu J, et al. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation. Invest Ophthalmol Vis Sci 2008;49(9):3821-3829.
30. Kong J, Kim SR, Binley K, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Therapy 2008;15(9):1311-1320.
31. Lu B, Malcuit C, Wang S, et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 2009;27(9):2126-2135.
32. Genead MA, Fishman GA, Stone EM, Allikmets R. The natural history of Stargardt Disease with specific sequence mutation of the ABCA4 gene. Invest Ophthalmol Vis Sci 2009;50(12):5867-5871.
33. Klevering BJ, Deutman AF, Maugeri A, Cremers FP, Hoyng CB. The spectrum of retinal phenotypes caused by mutations in the ABCA4 gene. Graefes Arch Clin Exp Ophthalmol 2005;243(2):90-100. (Pubitemid 40361630)